Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    GLUCOCORTICOID RECEPTOR
Show Display Options
Rank Status Study
1 Recruiting Difference in GC-induced Adrenal Insufficiency in RA Related to Polymorphisms in the Glucocorticoid Receptor Gene
Condition: Rheumatoid Arthritis
Intervention: Other: No intervention
2 Not yet recruiting A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Mifepristone;   Other: Placebo;   Drug: Nab-Paclitaxel
3 Recruiting Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Condition: Mild Hypercortisolism
Intervention: Drug: Mifepristone
4 Recruiting Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia
Condition: General Glucocorticoid Resistance
Intervention: Genetic: blood collection for mutation characterization
5 Completed Glucocorticoid Receptor Antagonism in Subclinical Cushings
Condition: Subclinical Cushing's
Intervention: Drug: Mifepristone
6 Enrolling by invitation The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease
Conditions: Glucose Homeostasis;   Protein Metabolism;   Lipid Metabolism;   Respiratory Function;   Connective Tissue Metabolism
Intervention:
7 Recruiting Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
Condition: Borderline Personality Disorder
Interventions: Drug: mifepristone;   Drug: Placebo
8 Enrolling by invitation FCM Analysis GR in Steroid-Treatment Patients
Condition: Healthy
Intervention:
9 Active, not recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Completed Effect of Symbicort on GR Localisation in Asthma
Condition: Asthma
Interventions: Procedure: Induced Sputum;   Drug: Symbicort, Formoterol, Budesonide and Placebo
11 Completed Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: ISIS-GCCRRx;   Drug: Placebo
12 Completed Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder
Conditions: Post-Traumatic Stress Disorders;   Healthy
Intervention:
13 Completed A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
Conditions: Asthma;   Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: AZD7594 inhalation powder (200 μg);   Drug: AZD7594 inhalation powder (400 μg);   Drug: AZD7594 pressurized inhalation suspension (200 μg);   Drug: AZD7594 placebo inhalation powder;   Drug: AZD7594 placebo pressurized inhalation suspension
14 Recruiting Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
Conditions: Solid Tumors;   Cellular Diagnosis, Ovarian Epithelial Cancer;   Breast Cancer
Intervention: Drug: CORT125134 with nab-paclitaxel
15 Completed
Has Results
The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen
Condition: Asthma
Interventions: Drug: AZD5423;   Drug: Budesonide 200 microgram;   Drug: Placebo
16 Completed The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
Condition: Healthy Adults
Interventions: Drug: Prednisone;   Drug: Placebo
17 Completed Brain Receptor Function in Post-Traumatic Stress Disorder
Condition: Post-Traumatic Stress Disorder
Intervention: Drug: RU-486 (Mifepristone)
18 Unknown  Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)
Condition: Glucocorticosteroid Refractory Acute GVHD
Intervention: Drug: Toclizumab
19 Recruiting An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Conditions: Advanced Cancer;   Metastatic Cancer
Intervention: Drug: INCAGN01876

Indicates status has not been verified in more than two years